12 research outputs found
Homocysteine and its relation to B-vitamins in Graves' disease before and after treatment: effect modification by smoking
No full textPredictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease
No full text
High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves’ disease for 12 months
No full textImpacto médico-social do tratamento medicamentoso da moléstia de Graves-Basedow em Hospital Público Universitário: avaliação retrospectiva e projeção prospectiva de conduta terapêutica
No full text
Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any)
No full textGraves\u2019 disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves\u2019 hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice
